TVM Capital Life Science leads international syndicate of investors – an additional EUR 3 million investment is expected later in 2015
Munich, 27 July 2015 — leon nanodrugs GmbH today announced that it completed the first closing of its Series A preferred stock offering at EUR 18.5 million. The financing was led by TVM Capital Life Science, based in Munich and Montreal, with participation from Signet Healthcare Partners (USA), LifeCare Partners (Switzerland), CD-Venture (Germany), Albany Private Equity Holding (Australia), and a non-disclosed Family Office from Germany. Dr. Hubert Birner, Managing Partner, and Stefan Fischer, General Partner & CFO, TVM Capital Life Science, James Gale, Managing Director, Signet Healthcare Partners, Dr. Gerhard Ries, Managing Partner, LifeCare Partners, Dr. Frank Mathias, CEO, Medigene AG, and Dr. Bernd Baumstümmler, CEO, Instillo Group, will be joining the Board of Directors.
leon-nanodrugs was founded by a group of experienced drug development professionals in mid-2011. The company focuses on the reformulation of approved or promising small molecule and protein drug candidates based on its patented and award winning MJR-nanotechnology-platform. leon-nanodrugs develops novel oral and parenteral formulations by using GMP (Good Manufacturing Practice) compliant nanotechnology to improve bioavailability, solubility as well as dissolution rates. leon-nanodrugs will use the proceeds of this Series A financing to expand its profitable service business and to enter into high margin co-development deals with pharmaceutical partners.
Dr. Wolfgang Beier, Medical Director and Co-Founder, explains: “With our unique network of interdisciplinary drug-development capabilities and our leading nanotechnology platform, we are a reformulation expert for high barrier generics for proactive product life-cycle-management or line-extensions as well as the development of novel nano- and micronized drugs.”
Cornelia Beier, Managing Director and Co-Founder of leon-nanodrugs adds: ”We are proud to partner with TVM Capital Life Science’s experienced investment team as the lead investor for our Series A financing. Their global reach will offer us unique opportunities to drive the commercialization of our product candidates on an international scale.”
“This is TVM Capital Life Science’s first investment into a German company since 2009 and we are very pleased to reinforce our footprint as a lead-investor in the German market, especially as we are joined in this financing by reputable investors who have co-invested with us over many years in Germany and abroad”, states Dr. Hubert Birner, Managing Partner with TVM Capital Life Science in Munich and Montreal. ”leon-nanodrugs provides an exciting next-generation-nanotechnology reformulation platform, validated by multiple service collaborations with prominent pharma partners, that will certainly change this market segment in the future – congratulations to the team at leon-nanodrugs for achieving one of the largest Series A financings in Germany this year.”
leon-nanodrugs GmbH (based in Munich) is a nanotechnology-based drug development company focused on reformulations and reinventions of drugs on a contract or co-development basis. Based on its “network of expertise”, leon-nanodrugs can provide a 360 degree service range – from concept to product approval. The core business is the reformulations to develop novel oral and parenteral formulations and innovative drug combinations, which have not been possible in the past due to low bioavailability caused by low solubility of APIs. The 2014 CPhI Pharma Awards for Best Innovation in Formulation was won by MJR PharmJet GmbH, leon nanodrugs’ exclusive reformulation service partner for its patented nanotechnology.
About TVM Capital Life Science
TVM Capital Life Science is providing venture capital to the international pharmaceutical, biopharmaceutical and medical technology industries with more than 30-years of transatlantic investment track record and in excess of US$1.3bn under management. TVM Capital Life Science currently invests from its 7th fund generation, TVM Life Science Ventures VII, with an integrated team of investment professionals from Munich and Montreal. www.tvm-capital.com or www.tvm-lifescience.com
About Signet Healthcare Partners
Founded in 1998, Signet Healthcare Partners provides growth capital to commercial-stage healthcare companies around the world. Over the past 16 years, Signet has organized three funds and completed investments in 42 companies with 25 exits. The team, comprised of five professionals with principal offices in New York City, brings over 100 years of collective healthcare experience in the specialty pharmaceutical, medical device, private equity and investment banking businesses. For more information, please visit Signet online at www.signethealthcarepartners.com.
About LifeCare Partners
LifeCare Partners is an independent investment firm providing financing to private and public life science companies. LifeCare Partners targets the entire life science industry with special focus on medical technology, diagnostics, biopharmaceuticals, food & nutrition, industrial biotechnology, biomaterials, e-health and bioenergy. Based in Basel, the LifeCare Partners team has successfully invested in more than 30 life science companies over the last years, of which a large number have already been listed on the stock exchange or have been acquired by leading players in the life science industry.
For more information, visit www.lifecarevc.com